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Bone tissue regeneration is amajor, worldwidemedical need, and several strategies have been developed to support the regeneration
of extensive bone defects, including stem cell based bone grafts. In addition to the application of stem cells with high osteogenic
potential, it is important to maintain proper blood flow in a bone graft to avoid inner graft necrosis. Mesenchymal stem cells
(MSCs) may form both osteocytes and endothelial cells; therefore we examined the combined in vitro osteogenic and endothelial
differentiation capacities of MSCs derived from adipose tissue, Wharton’s jelly, and periodontal ligament. Based on a detailed
characterization presented here, MSCs isolated from adipose tissue and periodontal ligament may be most appropriate for
generating vascularized bone grafts.
1. Introduction
There is a great clinical demand for improved methods
of bone tissue regeneration after trauma or medical bone
resections, as spontaneous recovery is slow or in many cases
nonexistent. This is well exemplified in critical-size bone
defects [1], which may affect the oral cavity as a result of
trauma, aggressive periodontitis, or tumor surgery [2]. Since
the availability of donor-derived bone grafts is limited and
the extraction of autologous bone grafts is often associated
with considerable pain and donor-site morbidity, there is
an increasing demand for in vitro engineered bone tissues
[3].
In order to help the bone healing process, recent tech-
nologies promote the use of various tissue grafts, containing
autologous or allogenic bone-forming cells. The cells used
in such a bone tissue regeneration therapy should have high
bone-forming potential for rapid and effective incorporation.
In addition to osteoblasts, cells promoting angiogenesis
should be also important participants in bone graft formation
and regeneration, especially in the case of large bone defects,
in order to promote osseointegration and avoid inner graft
necrosis. Clearly, to ensure the long-term function of the
bone graft, cells capable of forming blood vessels within the
bone tissue should also be present [4]. Stem or progenitor
cells capable of differentiating into both osteoblast and blood
vessel endothelial cell may provide a solution in this regard.
Mesenchymal stem cells (MSCs) are currently considered
to be key sources in regenerative medicine. MSCs are mul-
tipotent with self-renewal ability and a capacity to differen-
tiate into different mesenchymal lineages, including adipose
tissue, bone, and cartilage [5, 6]. Tissue-derived MSCs do
not raise major ethical concerns in medical applications [7].
In addition, due to their immunosuppressive characteristics
even allogeneic MSCs can be used in various therapeutic
approaches [8].
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MSCswere initially described in the bonemarrow stroma
[9] and later found in numerous human tissues including fat
and in different dental tissues [5, 10]. Bone marrow derived
(BM)MSCs have been used for tissue engineering for several
years. However, the invasive collection procedure of BM-
MSCs possesses disadvantages, including pain and poten-
tial medical complications [5]. MSCs from adult adipose
tissue (AD-MSCs) can be readily harvested in large numbers
with very low donor-site morbidity. AD-MSCs therefore are
broadly used in various regenerative therapeutic interven-
tions and may also serve as cells for bone grafts [11]. In
additionWharton’s jelly of the umbilical cord (WJ-MSC) and
the tissues of the placenta also provide a rich source of MSCs
for potential therapies [12].
The periodontal ligament is a soft connective tissue devel-
oped from the neural crest and has anchoring, homeostatic,
and regenerative functions in the periodontium. Periodontal
ligament contains stem cells (PDLSC) possessing MSC prop-
erties [10, 13].The enhanced osseointegration effect of human
PDLSCs was confirmed after transplantation of these cells
with bone graft [14].
In the present work we have compared several properties
of in vitro cultured and differentiated human AD-MSCs,
WJ-MSCs, and PDLSCs. Under identical conditions we have
examined their frequency of colonies, immunophenotype,
trilineage differentiation capacity, and the expressed pluripo-
tency and mesodermal markers. Furthermore, we have char-
acterized in detail the endothelial differentiation capacity of
these MSCs.
2. Materials and Methods
2.1. Isolation, Culturing, and Differentiation of Cells. All sam-
ples were obtained from healthy donors. Work with human
tissues was performed with the permission of the Ethical
Committee of the Hungarian Medical Research Council
(ETT; ID: 24083-3/2013/HER). Most of the reagents below
were purchased from Thermo Fisher Scientific (Waltham,
USA), all others as indicated.
MSCs from liposuction derived adipose tissue (𝑛 = 3)
and periodontal ligament (𝑛 = 3) were isolated as described
previously [13, 15]. Wharton’s jelly of the umbilical cord was
collected from full-term births (𝑛 = 3). The anatomical
localization of the periodontal ligament and Wharton’s jelly
is presented on Figure 1.
For isolation of Wharton’s jelly derived MSC, the cord
was cut into 1-2 cm segments and the vessels were removed.
The outstretched tissue was treatedwith 2mg/mL collagenase
type IV and 100 IU/mL hyaluronidase (Sigma-Aldrich, St.
Louis, USA). The cord pieces were washed with DMEM
medium and Wharton’s jelly was collected and passed
through an 18G needle. The cell suspension was then resus-
pended in high glucose DMEMmedium supplemented with
20% fetal bovine serum (FBS) and 16 ng/mLfibroblast growth
factor 2. Cells were plated with 2 × 105/cm2 density. Growth
medium (DMEM-F12 1 : 1 with 10% FBS, 2mM L-glutamine,
and 50 𝜇g/mL gentamicin plus 1 ng/mL FGF-2) was used after
third medium changes, and cells were subcultured once a
week at a density of 4 × 103/cm2.
To assess the differentiation potential of the MSC iso-
lates, cells between passages 4 and 8 were differentiated
into adipocyte, osteoblast, and chondrocyte phenotypes as
documented [13].
Human umbilical vein endothelial cells (HUVEC) were
kind gifts of Adrienn Ne´meth. The isolation method and
culture conditions were detailed by [16].
The human embryonic stem cell line 9 (HUES9) was a
kind gift of Douglas Melton, Harvard University, USA. The
HUES culture conditions were used as described in detail by
Apa´ti et al. [17].
2.2. Flow Cytometry. The expression of cell surface immuno-
markers was assessed by flow cytometry [13]. Cells were
stained with the following mouse monoclonal antibodies:
anti-human CD13, CD14, CD29, CD31, CD34, CD44, CD45,
CD73, CD90, CD105, CD106, CD117, CD133, CD144, CD146,
CD166, CD271, CD309, and HLA-DR or the corresponding
isotype controls. For references of the antibodies see Supple-
mentary Table 1 in Supplementary Material available online
at http://dx.doi.org/10.1155/2016/3595941. Dead cells were
identified by staining with propidium iodide. Measurements
were carried out in a 4-color FACSCalibur flow cytometer
(BD Biosciences). In the case of ABCG2, unconjugated 5D3
monoclonal antibody was used as described previously [13].
Data were expressed both as mean percentage of positive
cells and as median fluorescence intensity (MFI) ratio deter-
mined using the median fluorescence value of the specific
marker analyzed, divided by the median fluorescence value
of the isotype control.
2.3. Colony Forming Unit-Fibroblast Assay (CFU-F). The
CFU-F assay was performed at passages 3–6 as previously
described [13].
2.4. Immunocytochemistry. Cells were fixed [15] and stained
with unconjugated monoclonal anti-𝛼-smooth muscle actin
(𝛼-SMA; Sigma-Aldrich; cat. number: A5228) or anti-GATA6
(R&D Systems Minneapolis, USA; cat. number: AF1700)
primary antibody or the matched isotype control for 1 hour
at room temperature in the dilution according to man-
ufacturer’s instructions. AlexaFluor488 (𝛼-SMA) or Alex-
aFluor568 (GATA6) secondary antibodies were applied for
fluorescent detection, and nuclei were counterstained with
DAPI. The fluorescence membrane stain DiSC3(5) was used
in final concentration of 5𝜇M.
2.5. Endothelial Differentiation and Matrigel Tube Formation
Assay. Cells were stimulated with Endothelial Cell Growth
Medium (EGM-2, Lonza, Basel, Switzerland) for 7 days in
a humidified thermostat. Chilled Matrigel (Corning, New
York, USA) was added to a 24-well plate and incubated at
37∘C. 5 × 104 of the induced cells were suspended in EGM-2
medium and added to the solidified Matrigel. Morphological
changes were observed under an inverted microscope during
a 24-hour incubation period. Representative pictures were
taken in every hour and analyzed using the TubeCount
software [18] to determine the number and length of tubes.
When a maximum level of tube forming was observed, three
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Figure 1: Schematic cross-sectional diagramof humanumbilical cord (a) and tooth (b) shows anatomical compartments, includingWharton’s
jelly (a) and periodontal ligament (b), as a source of stem cells.
pictures were taken fromdifferent fields of eachwell.The data
were presented as averages of three different experiments.
2.6. Gene Expression Analysis. Total RNA was isolated from
undifferentiated and differentiated cells and cDNA was syn-
thesized [15].The expression levels ofOCT4, SOX2,NANOG,
telomerase reverse transcriptase (TERT), tissue-nonspecific
alkaline phosphatase (ALP), peroxisome proliferator-acti-
vated receptor gamma (PPAR𝛾), and platelet endothelial
cell adhesion molecule 1 (PECAM1) genes were measured
using TaqMan reagents. The expression of runt-related tran-
scription factor 2 (RUNX2) mRNA was determined by using
Power SYBR Green reagents in StepOne Plus qPCR instru-
ments (Thermo Fisher Scientific). Gene expression levels
were calculated with 2(−ΔCt) method relative to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) as a reference.
For references of the primers see Supplementary Table 2.
2.7. Statistical Analysis. The data are presented as the mean
of three repeated experiments of the biological parallels ± SD.
Statistical comparisons were performed using Student’s t-test.
𝑃 values <0.001 were considered significant.
3. Results
3.1. Colony Forming Unit-Fibroblast Assay. The efficiency by
which MSCs can form colonies at low densities on the plastic
surface still remains an important assay for the quality control
of cell preparations. (The heterogeneity of the different MSC
isolates is demonstrated in Figure 2(a).) PDLSCs produced
94.3 ± 27.0 colonies from 400 cells which is significantly
higher than in the case of AD-MSC (46.3 ± 21.0) or WJ-MSC
(24.2 ± 8.9) isolates (Figures 2(b) and 2(c)).
3.2. Cell Surface Markers. The immunophenotypic profile of
adherent cells from each culture was determined by testing
a panel of surface markers using flow cytometry. Essentially,
100% of all the different MSCs expressed the most commonly
reported positive markers CD13, CD29, CD44, CD73, CD90,
CD105, and CD166. Endothelial markers CD31, CD144, and
CD309 and themarkers involved in hematopoiesis like CD14,
CD34, CD45, CD117, or CD133 and HLA-DR were absent or
indeterminably low. It should be noted that CD90 expression
decreased during passages in the case of a WJ-MSC iso-
late.
In agreement with the data in the literature, the vascular
cell adhesion molecule 1 (VCAM-1, CD106) was present in a
small subpopulation of the PDL (20.6 ± 4.5%) derived cells,
while AD-MSCs andWJ-MSCs failed to express this marker.
The melanoma cell adhesion molecule (MCAM, CD146),
known as a pericyte marker, was present in 25–55% of the
WJ-MSC and PDL cells, while AD-MSCs, in contrast to data
in the literature, did not express CD146 (Figure 2(d)).
The common MSC markers were found to be present in
all cell types examined, while marker density was variable in
the MSCs from different tissue sources. The presence or the
expression level of amarker inMSCs usually refers to a special
property of the cell. For example, it has been described that
CD29, CD44, CD73, CD90, CD105, and CD166 have roles
in the multilineage differentiation processes [19–21]. Thus we
tried to establish a correlation between the expression levels
of these surface markers and the osteogenic, adipogenic, or
angiogenic differentiation potential of the MSC isolates from
different tissue sources.The expression intensity of the mark-
ers was determined by flow cytometry. In our experiments
we found thatThy-1 (CD90) was present at high levels on the
surface ofAD-MSCs andPDLSCs,while thismarker levelwas
low in the case of WJ-MSCs.The ectonucleotidase CD73 was
expressed at significantly higher levels in the PDL cells, as
compared to other MSC isolates. Furthermore, the integrin
family member CD29 was expressed only modestly in AD-
MSCs (Figure 2(e)).
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Figure 2: Heterogeneity of the different MSC samples. The morphology of the cells was demonstrated with Giemsa staining (a). The colony
forming ability ofMSCswas investigated on 10 cmpetri dishes (b). Colony forming efficiencywas calculated as the number of colonies divided
by the total number of seeded cells (c). The CD106 and CD146 expression in different MSC isolates determined by flow cytometry (d). The
expression levels of CD90, CD73, and CD29 markers of MSC samples were determined with flow cytometry and represented as median
fluorescence intensities (MFI) (e). The photos demonstrate representative samples. ∗∗∗𝑃 value less than 0.001.
3.3. Osteogenic, Adipogenic, andChondrogenic Differentiation.
The trilineage differentiation capacity of MSCs was con-
firmed by standard induction protocols. The bone-forming
ability ofMSCs was followed by RT-qPCR analysis of RUNX2
and ALP mRNA expression after 7 days of differentiation in
an osteogenic medium. RUNX2 is the master transcription
factor in osteogenic development, while ALP is recognized
as an early marker of osteoblastic differentiation and indis-
pensable for extracellular matrix maturation. When induced,
all cell types showed upregulated expression of RUNX2,
and no significant differences were noticeable between MSC
isolates in this expression (Figure 3(a)). After stimulation, the
increased expression levels of ALP mRNA were found to be
similar in AD-MSCs and PDLSCs, while significantly lower
ALP gene expression was observed in the WJ-MSC samples
(Figure 3(b)).
After 14 days of osteogenic MSC differentiation induc-
tion, alizarin red staining was performed to directly visu-
alize the mineralization of the extracellular matrix in these
cultures. The quantification of the staining showed the high
calcium accumulation in AD-MSC and PDLSC isolates. The
mineralization capability of WJ-MSCs lagged far behind
those observed in MSCs from other tissues (Figures 3(c) and
3(d)). We observed significant correlation between the CD90
expression patterns and the levels of calcium deposition in
the different MSC isolates (Figure 2(e)).
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Figure 3:The trilineage differentiation ability ofMSC isolates.The expression level of theRUNX2 (a) andALP (b) genes in the undifferentiated
and differentiated samples, determined with RT-qPCRmeasurements. Alizarin red staining was used to demonstrate the calcium deposition
of the matured bone matrix after 14 days of osteogenic induction (c). The stain was dissolved and quantified colorimetrically (d). Lipid
accumulation was confirmed by oil red O staining (red dots) after adipogenic induction; cells were counterstained with dimethyl methylene
blue stain (e). The concentration of the red stain was determined colorimetrically (f). The adipogenesis was followed with RT-qPCR
measurement of PPAR𝛾 gene (g). Chondrogenic differentiation was confirmed in all samples (h). The photos demonstrate representative
samples. ∗∗∗𝑃 value less than 0.001.
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Figure 4: Endothelial differentiation potential of the MSCs was tested in Matrigel tube formation assay. Tubular-like structures were
photographed (a) and analyzed with TubeCount software. Human umbilical vein endothelial cells (HUVEC) were used as controls. Total
tube length (b) and numbers (c) were counted and presented in the diagrams. The changes in the expression of PECAM1 during endothelial
differentiation were followed with RT-qPCR. Samples were collected from undifferentiated and predifferentiated states (7-day endothelial
induction) and after angiogenesis in a Matrigel assay (d). The 3D network developed by a representative PDLSC sample was demonstrated
with fluorescence staining of the cell membrane byDiSC3(5) (red) and the nucleus byDAPI (cyan) (e).The photos demonstrate representative
samples. ∗∗∗𝑃 value less than 0.001.
In the adipogenic differentiation experiments AD-MSCs
accumulated significantly higher amounts of lipids, as com-
pared to the other MSC preparations (Figures 3(e) and 3(f)).
The mRNA expression levels of PPAR𝛾, a key factor in
adipogenesis, were in close correlation with the amounts
of lipid deposition, indicating that AD-MSCs can produce
adipocytes most effectively (Figure 3(g)). We found that
CD29 expression levels in AD-MSCs were the lowest (Fig-
ure 2(e)); thus CD29 expression may be inversely related to
the adipogenic differentiation potential as in accordance with
the findings of Rodeheffer et al. [22].
We have also performed chondrogenic differentiation of
the various MSC preparations. We found that all MSC types
were capable for this differentiation (Figure 3(h)).
3.4. Endothelial Differentiation. The endothelial forming
potential of theMSCs was examined in an angiogenesis assay,
wherein we found that AD-MSCs and WJ-MSCs reached
a maximum tube-forming potential between 3 and 7 hours
after seeding, while the PDLSCs needed 18–20 hours to form
a well-developed capillary-like tubule network. The tube-
forming potential of AD-MSCs and PDLSCs was similar to
that observed in the HUVEC, while the tubular networks
formed by WJ-MSCs were significantly less developed, as
compared to other isolates (Figures 4(a), 4(b), and 4(c)).
Moreover, the tubes generated by MSCs derived from dif-
ferent tissues showed significantly different phenotypes. AD-
MSCs and WJ-MSCs formed relatively short tubes and the
tubes of WJ-MSCs were much thicker than those formed
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Figure 5: Pluripotency and mesodermal markers of MSCs. The embryonic stem cell marker ABCG2 was detectable uniquely in PDLSCs,
while a remarkable SSEA4 expressing population was found inWJ-MSC isolates, as determined by flow cytometer (a). Immunohistochemical
staining of GATA6 (red, DAPI-blue) (b) and 𝛼-SMA (green, DAPI-blue) (c) showed significant expression only in WJ-MSCs. The photos
demonstrate representative samples. ∗∗∗𝑃 value less than 0.001.
by the other MSC isolates. The extensive tubular network
formed by PDLSC mostly consisted of long and thin tubes,
resembling capillaries. A characteristic sample of a tubular
network formed by fluorescently stained PDL stem cells is
demonstrated in Figure 4(e).
Themessenger RNA expression of the endothelial specific
marker PECAM1 was analyzed by real-time qPCR after
prestimulation of the MSCs and after retrieval of the cells
from the Matrigel (Figure 4(d)). An elevation in PECAM1
mRNA expression level was observed after the induction in
all MSC preparations. Furthermore, an additional elevation
was noticeable in the expression of PECAM1 when the cells
formed endothelial structures. However, PECAM1 mRNA
expression was still significantly smaller as compared to that
found in the HUVEC, in which no further activation of
this gene expression was observed either in an angiogenesis
inducing medium or in the Matrigel environment.
All these results indicate a higher endothelial differentia-
tion ability and vessel-forming potential of PDLSCs and AD-
MSCs, as compared to the WJ-MSCs.
3.5. Expression of Pluripotency andMesodermalMarkers in the
MSC Preparations. In these experiments we have examined
whether WJ-MSCs, suggested to be in more early stages
of stem cell development, express any special pluripotency
markers. The expression of mRNA of transcription factors
indicating a pluripotent stem cell state, including OCT4,
SOX2, Nanog, or that of TERT, a major factor in maintaining
self-renewal capacity, was not detectable in either of the
MSC isolates examined here (data not shown). However,
the stage-specific embryonic antigene-4 (SSEA-4), a marker
of undifferentiated state in human embryonic stem cells,
was present in a remarkable quantity on the surface of the
WJ-MSCs (37–65%), in contrast to that found in AD-MSCs
and PDLSCs (6–8%). The presence of the ABCG2 protein,
another potential stem cell marker, was detectable with flow
cytometry exclusively in the PDLSCs (Figure 5(a)).
In immunocytochemistry studies the mesodermal mark-
er proteins, 𝛼-SMA, typically expressed in smooth muscle
cells, and the transcription factor GATA6, were observable
only in WJ-MSCs (Figures 5(b) and 5(c)).
4. Discussion
MSCs derived from diverse tissues share some common
properties [6]; however, on closer examination, cells with
very heterogeneous properties can be foundwithin individual
isolates in the expression of various markers. The colony
forming capacity and the differentiation potential of these
isolates can vary as well.
In this study we found that the expression levels of
CD90, CD73, and CD29 were variable, but representative
for the MSCs isolated from different tissue sources. Here
we observed that AD-MSCs and PDLSCs expressed higher
CD90 levels and showed greater bone and endothelial differ-
entiation ability, as compared to WJ-MSCs. In the literature
an enhanced bone regeneration potential of AD-MSCs with
high level expression of Thy-1 has already been found [23].
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These data suggest that MSCs with high CD90 expression
may have the ability to differentiate into both bone and
endothelial cells.
The use of MSCs for tissue engineering applications was
found to be safe [24].Themost relevant question in bone graft
tissue engineering is how efficiently a progenitor cell can form
bone nodules. In our experiments the calcification potential
ofAD-MSCswas similar to PDLSCs.However, the osteogenic
capacity of WJ-MSCs was significantly lower, as compared
to MSCs from other tissue sources. This observation is in
agreement with the results of Yu et al. [25], reporting that
differentiated PDLSCs showed a better mineral deposition as
compared to WJ-MSCs, although no significant differences
were observed in the upregulation of RUNX2 gene expression
in these MSCs. The elevation in RUNX2 mRNA expression
indicates the beginning of the ossification process, while
in this period no matured osteoblasts can be developed as
yet, as suggested by a low level ALP expression, which is
an important factor in matrix maturation [26]. The high
RUNX2 and low ALP mRNA levels in the WJ-MSCs may
explain the relatively low calcification potential of these
cells.
Here we showed that none of the examined MSCs
expressed the classical embryonic stem cell markers OCT4,
SOX2, hTERT, or Nanog. ABCG2, a potential pluripotency
marker, was uniquely detectable at a relative high level on
the surface of PDLSCs.The findings thatWJ-MSCs expressed
the highest level of the pluripotency marker SSEA-4 and only
WJ-MSCs expressed 𝛼-SMA and GATA6 protein altogether
indicate that this cell type is at an earlier stage of stem
cell development. It may also explain the need for a longer
induction time in in vitro differentiation experiments [27].
It is in accordance with the findings of Kubo et al. [28],
whereas the knockdown of GATA6 expression by siRNA
suppressed the self-renewal capacity of human MSCs. The
limited differentiation potential of 𝛼-SMA expressing MSCs
has already been reported [29]; however the role of SSEA-4 in
the maintenance of pluripotency is still controversial [30, 31].
It is important to find the most suitable cell types and
techniques tomaintain proper blood flow inside of large bone
grafts [5]. MSC therapy has been considered as an alternative
clinical intervention. On one hand MSCs help healing by
support angiogenesis, mediated by paracrine factors (e.g.,
VEGF). On the other hand, the endothelial differentiation
ability of the transplanted MSCs directly leads to vessel
formation. It has been demonstrated in clinical studies that
transplantation of allogenicMSCs to the affected area is a safe
and efficient procedure to promote regenerative vasculariza-
tion [32]. Furthermore, the angiogenic potential of dental
pulp derived stem cells has already been observed [33], indi-
cating that dental stem cells can be suitable candidates
to achieve complex bone replacement. Here we show that
PDLSCs can form endothelial structures as effectively as AD-
MSCs and thus may generate proper vasculature in bone
grafts.
The main therapeutic advantage of AD-MSCs, namely,
their availability in large numbers, may be overcome by the
faster proliferation rates of PDLSCs (data not shown), while a
disadvantage of these latter MSCs is the need for their ex vivo
culturing to reach the required cell number for therapeutic
applications.
As a summary, AD-MSCs and PDLSCs seem to be both
suitable for complex bone replacement applications, com-
plemented with a vascular network formed by the same
donor cell types. These detailed in vitro studies may signif-
icantly promote further use of MSCs in in vivo therapeutic
approaches in bone regeneration.
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